Xenetic Biosciences, Inc. — 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014; filed April 15, 2015. This is an annual filing, not a standalone fourth-quarter report. Xenetic is a clinical-stage biopharmaceutical company developing drug candidates using PolyXen, OncoHist and ImuXen platforms. No candidate had marketing approval. The January 2014 acquisition of Xenetic UK was accounted for as a reverse acquisition, so the comparative financial statements principally continue Xenetic UK’s historical results.
Financial performance and position
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $0 | $1.0 million |
| Research and development expense | $6.32 million | $3.08 million |
| General and administrative expense | $6.60 million | $6.46 million |
| Operating loss | $12.92 million | $8.55 million |
| Net loss | $14.31 million | $8.58 million |
| Net loss per share, basic and diluted | $0.11 | $0.07 |
| Net cash used in operating activities | $12.33 million | $6.05 million |
Gross profit was zero in 2014; 2013 gross profit was $1.0 million, with no cost of revenue. A meaningful operating margin is not applicable given the absence of 2014 revenue. The 2013 revenue was a one-time Baxter license payment, not product sales. The company reported no income tax expense.
At December 31, 2014, cash was $2.51 million, current assets $2.78 million, current liabilities $2.70 million and working capital approximately $78,000. Total liabilities were $5.84 million, including $395,000 in loans due to related parties and a $3.08 million deferred tax liability. Stockholders’ equity was $10.48 million. The filing identifies approximately $635,000 of current-liability balances as disputed. Cash fell from $4.84 million at year-end 2013. The company received $10 million from Baxter’s equity investment, partly offsetting cash burn; operating cash use was $12.33 million.
Changes and notable items
- R&D expense more than doubled, mainly due to OncoHist IND-enabling preclinical work and increased external CRO and research services. G&A was broadly flat, with higher public-company legal, accounting, investor-relations and insurance costs offset by lower acquisition-related contractor costs.
- Revenue declined from $1.0 million to zero. The Baxter collaboration generated no revenue in 2014; its 2013 revenue was the upfront license fee.
- Net loss increased by $5.73 million. Other items included a $1.07 million loss on disposal of subsidiaries under the Hive Out Agreement, foreign-exchange-related expense, and approximately $812,000 of R&D expense for shares issued to FDS Pharma in connection with IP assignment and termination of a prior collaboration.
- Cash financing included Baxter’s $10 million share purchase. The company also repaid approximately $286,000 on a related-party loan. The 2014 year-end share count was 149,985,476 issued shares; warrants and additional financing could further dilute shareholders.
- No impairment was recorded for goodwill or indefinite-lived in-process R&D assets in 2014. OncoHist’s carrying value was approximately $9.75 million; its fair value estimate depends on projections, including future milestones and royalties.
Outlook, liquidity and risks
Management estimated that available cash would fund the base business plan only through the end of April 2015. The auditor’s report and management disclosed substantial doubt about the company’s ability to continue as a going concern. Management was pursuing bridge financing, including proposed senior secured convertible notes of up to $3 million expected to yield about $2.8 million net, and a registered debt or equity offering targeted by September 2015. The company said it needed at least $9 million of additional net capital before September 2015 to fund planned operations through April 2016. These financings were plans under discussion, not completed transactions as of the filing. Failure to obtain funding could force cuts, delays or suspension of development programs.
- Pipeline plans: ErepoXen was in Phase II dose-ranging work in Australia/New Zealand, with further partner-led studies in India and Russia. Management was pursuing out-licensing to share later-stage development costs. OncoHist AML was a 2015 priority; the company planned an FDA IND and US Phase I/II(a) trial, but did not expect trial commencement before year-end 2015 and needed additional capital. Baxter expected to begin human trials for its Factor VIII candidate in the first half of 2016; milestone receipts depend on Baxter achieving contractual milestones, with up to $100 million in potential payments plus royalties.
- Development uncertainty: All candidates remained investigational. Trials can fail or be delayed; the Russian OncoHist AML trial was stopped after a change in local standard of care, and partner programs had experienced delays.
- Partner and supply concentration: Historically, revenue relied substantially on Baxter. The company depends on collaborators for development and on third parties for clinical materials; it lacked in-house manufacturing capacity and was seeking an alternative OncoHist supplier.
- Governance and ownership: SynBio held approximately 41.6% of issued common stock at year-end and was an affiliate; Baxter and Serum Institute were also shareholders and collaboration partners. The company disclosed related-party loans, services and partner warrants.
- Market and IP risks: Shares traded on the OTCQB, with limited liquidity and penny-stock restrictions. The filing cites substantial financing, dilution, regulatory, clinical, competition and intellectual-property risks. No material legal proceedings were reported.
Investor verification priorities
- Confirm whether the proposed bridge notes and subsequent public offering closed, their terms, and the resulting cash runway and dilution.
- Review subsequent filings for going-concern status, cash burn, disputed liabilities and repayment arrangements for related-party balances.
- Verify current clinical progress and results for ErepoXen and OncoHist, including IND timing, manufacturing readiness and whether trials were initiated.
- Track Baxter’s Factor VIII development milestones and contractual conditions for any milestone payments or royalties; the potential $100 million is contingent, not assured.
- Assess the effect of warrants, options and future financing on fully diluted share count, and review related-party approvals and terms.
- Monitor OncoHist impairment assumptions and any new impairment charges, given the asset’s reliance on uncertain future development and commercial projections.